查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1729649

日本胰島素藥物傳輸設備市場報告（按類型（藥物、設備）和地區）2025-2033

Japan Insulin Drugs Delivery Devices Market Report by Type (Drug, Device), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

2024 年，日本胰島素藥物傳輸設備市場規模達 20 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 39 億美元，2025-2033 年期間的成長率 (CAGR) 為 6.75%。日本糖尿病發生率的不斷上升，加上新的胰島素製劑和需要專門輸送裝置的藥物的開發，是推動市場發展的主要因素。

胰島素藥物輸送裝置對於糖尿病患者來說是必不可少的工具，糖尿病是一種以胰島素產生或利用受損為特徵的慢性疾病。這些設備可以精確、方便地注射胰島素，胰島素是一種對調節血糖水平至關重要的荷爾蒙。胰島素傳遞領域最顯著的進步之一是胰島素筆，它類似於普通筆，只需按一下按鈕即可實現精確劑量。其精巧的設計和便攜性使其成為 1 型和 2 型糖尿病患者的熱門選擇。此外，胰島素幫浦提供持續的皮下胰島素輸注，模擬體內自然的胰島素釋放。這些設備可以精確控制胰島素劑量，並可根據個人的獨特需求進行程式設計。此外，與行動應用程式和連續血糖監測儀相結合的智慧胰島素輸送系統的開發進一步改善了糖尿病管理。這些設備能夠即時追蹤血糖水平並自動調整胰島素，減輕患者持續監測和決策的負擔。

日本胰島素藥物輸送裝置市場趨勢：

日本的胰島素藥物輸送裝置市場有望大幅成長，這主要得益於幾個引人注目的促進因素。首先，糖尿病盛行率的上升是推動市場擴張的關鍵因素。此外，患者和醫療保健提供者對糖尿病管理的認知不斷提高，以及及時注射胰島素的重要性，也促進了市場的上升趨勢。此外，胰島素輸送裝置的技術進步，例如智慧胰島素筆和穿戴式胰島素幫浦的開發，正在提高患者的便利性和依從性。此外，老年人口的不斷成長使得他們更容易患糖尿病，這也增加了對這些設備的需求。除此之外，日本不斷上升的肥胖率和久坐不動的生活方式加劇了第 2 型糖尿病的發生率，進一步刺激了胰島素藥物輸送設備市場的發展。此外，對個人化醫療和客製化胰島素療法的追求正在促進設備設計和功能的創新。此外，糖尿病管理產品的優惠報銷政策預計將在預測期內推動日本市場的發展，這將激勵患者採用先進的胰島素藥物輸送裝置。

日本胰島素藥物輸送裝置市場區隔：

類型洞察：

  • 藥物
    • 基礎胰島素或長效胰島素
  • 來得時（甘精胰島素）
  • Levemir（地特胰島素）
  • Toujeo（甘精胰島素）
  • Tresiba（德谷胰島素）
  • Basaglar（甘精胰島素）
    • 推注胰島素或速效胰島素
  • NovoRapid/Novolog（門冬胰島素）
  • Humalog（賴脯胰島素）
  • Apidra（胰島素谷離胺酸）
  • FIASP（門冬胰島素）
  • Admelog（賽諾菲賴脯胰島素）
    • 傳統人類胰島素
  • 諾和靈/Mixtard/Actrapid/Insulatard
  • 優泌林
  • 因蘇曼
    • 組合胰島素
  • NovoMix（雙相門冬胰島素）
  • Ryzodeg（德谷胰島素和門冬胰島素）
  • Xultophy（德谷胰島素和利拉魯肽）
  • Soliqua/Suliqua（甘精胰島素和利西拉來）
    • 生物相似藥胰島素
  • 甘精胰島素生物相似藥
  • 人類胰島素生物相似藥
  • 裝置
    • 胰島素幫浦
  • 胰島素幫浦裝置
  • 胰島素幫浦儲液器
  • 胰島素輸注器
    • 胰島素筆
  • 可重複使用筆中的墨盒
  • 一次性胰島素筆
    • 胰島素注射器
    • 胰島素噴射器

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

  • 日本胰島素藥物輸送裝置市場迄今表現如何，未來幾年將如何表現？
  • COVID-19 對日本胰島素藥物輸送裝置市場有何影響？
  • 日本胰島素藥物輸送裝置市場依類型分為哪些類型？
  • 日本胰島素藥物輸送裝置市場的價值鏈分為哪些階段？
  • 日本胰島素藥物輸送裝置的主要促進因素和挑戰是什麼？
  • 日本胰島素藥物輸送裝置市場的結構是怎麼樣的？主要參與者是誰？
  • 日本胰島素藥物輸送裝置市場的競爭程度如何？

本報告回答的關鍵問題：

  • 日本胰島素藥物輸送裝置市場迄今表現如何，未來幾年將如何表現？
  • COVID-19 對日本胰島素藥物輸送裝置市場有何影響？
  • 日本胰島素藥物輸送裝置市場依類型分為哪些類型？
  • 日本胰島素藥物輸送裝置市場的價值鏈分為哪些階段？
  • 日本胰島素藥物輸送裝置的主要促進因素和挑戰是什麼？
  • 日本胰島素藥物輸送裝置市場的結構是怎麼樣的？主要參與者是誰？
  • 日本胰島素藥物輸送裝置市場的競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：日本胰島素藥物輸送裝置市場 - 簡介

  • 概述
  • 市場動態
  • 產業趨勢
  • 競爭情報

第5章：日本胰島素藥物輸送裝置市場格局

  • 歷史與當前市場趨勢（2019-2024）
  • 市場預測（2025-2033）

第6章：日本胰島素藥物輸送裝置市場-分類：依類型

  • 藥物
    • 概述
    • 市場區隔
      • 基礎胰島素或長效胰島素
        • 來得時（甘精胰島素）
        • Levemir（地特胰島素）
        • Toujeo（甘精胰島素）
        • Tresiba（德谷胰島素）
        • Basaglar（甘精胰島素）
      • 推注胰島素或速效胰島素
        • NovoRapid/Novolog（門冬胰島素）
        • Humalog（賴脯胰島素）
        • Apidra（胰島素谷離胺酸）
        • FIASP（門冬胰島素）
        • Admelog（賽諾菲賴脯胰島素）
      • 傳統人類胰島素
        • 諾和靈/Mixtard/Actrapid/Insulatard
        • 優泌林
        • 因蘇曼
      • 組合胰島素
        • NovoMix（雙相門冬胰島素）
        • Ryzodeg（德谷胰島素和門冬胰島素）
        • Xultophy（德谷胰島素和利拉魯肽）
        • Soliqua/Suliqua（甘精胰島素和利西拉肽）
      • 生物相似藥胰島素
        • 甘精胰島素生物相似藥
        • 人類胰島素生物相似藥
  • 裝置
    • 概述
    • 市場區隔
      • 胰島素幫浦
        • 胰島素幫浦裝置
        • 胰島素幫浦儲液器
        • 胰島素輸注器
      • 胰島素筆
        • 可重複使用筆中的墨盒
        • 一次性胰島素筆
      • 胰島素注射器
      • 胰島素噴射器

第7章：日本胰島素藥物輸送裝置市場-競爭格局

  • 概述
  • 市場結構
  • 市場參與者定位
  • 最佳獲勝策略
  • 競爭儀錶板
  • 公司評估象限

第8章：關鍵參與者簡介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第9章：日本胰島素藥物輸送裝置市場-產業分析

  • 促進因素、限制因素和機遇
    • 概述
    • 驅動程式
    • 限制
    • 機會
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 價值鏈分析

第 10 章：附錄

簡介目錄
Product Code: SR112025A15120

Japan insulin drugs delivery devices market size reached USD 2.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.75% during 2025-2033. The increasing incidences of diabetes in Japan coupled with the development of new insulin formulations and drugs that require specialized delivery devices are primarily driving the market.

Insulin drugs delivery devices are essential tools for individuals suffering from diabetes, a chronic condition characterized by impaired insulin production or utilization. These devices enable precise and convenient administration of insulin, a hormone crucial for regulating blood sugar levels. One of the most notable advancements in insulin delivery is the insulin pen, which resembles a regular pen and allows for accurate dosing with a simple push of a button. Its discreet design and portability have made it a popular choice for type 1 and type 2 diabetics. Additionally, insulin pumps offer continuous subcutaneous insulin infusion, mimicking the natural insulin release in the body. These devices provide precise control over insulin dosage and can be programmed to match an individual's unique needs. Furthermore, the development of smart insulin delivery systems, which integrate with mobile apps and continuous glucose monitors, has further improved diabetes management. These devices enable real-time tracking of blood sugar levels and automated insulin adjustments, reducing the burden of constant monitoring and decision-making for patients.

Japan Insulin Drugs Delivery Devices Market Trends:

The insulin drugs delivery devices market in Japan is poised for significant growth, primarily due to several compelling drivers. Firstly, the rising prevalence of diabetes is a pivotal factor propelling market expansion. Moreover, the increasing awareness about diabetes management and the importance of timely insulin administration among patients and healthcare providers is contributing to the market's upward trajectory. Additionally, technological advancements in insulin delivery devices, such as the development of smart insulin pens and wearable insulin pumps, are driving patient convenience and adherence. Furthermore, the growing geriatric population, who are more susceptible to diabetes, is augmenting the demand for these devices. Apart from this, the escalating obesity rates and sedentary lifestyles in Japan are fueling the incidence of type 2 diabetes, further bolstering the insulin drugs delivery devices market. Additionally, the pursuit of personalized medicine and tailored insulin therapies is fostering innovation in device design and functionality. Moreover, favorable reimbursement policies for diabetes management products, which incentivize patients to adopt advanced insulin drugs delivery devices, are expected to drive the market in Japan during the forecast period.

Japan Insulin Drugs Delivery Devices Market Segmentation:

Type Insights:

  • Drug
    • Basal or Long-Acting Insulins
  • Lantus (Insulin Glargine)
  • Levemir (Insulin Detemir)
  • Toujeo (Insulin Glargine)
  • Tresiba (Insulin Degludec)
  • Basaglar (Insulin Glargine)
    • Bolus or Fast-Acting Insulins
  • NovoRapid/Novolog (Insulin aspart)
  • Humalog (Insulin lispro)
  • Apidra (Insulin glulisine)
  • FIASP (Insulin aspart)
  • Admelog (Insulin lispro Sanofi)
    • Traditional Human Insulins
  • Novolin/Mixtard/Actrapid/Insulatard
  • Humulin
  • Insuman
    • Combination Insulins
  • NovoMix (Biphasic Insulin aspart)
  • Ryzodeg (Insulin degludec and Insulin aspart)
  • Xultophy (Insulin degludec and Liraglutide)
  • Soliqua/Suliqua (Insulin glargine and Lixisenatide)
    • Biosimilar Insulins
  • Insulin Glargine Biosimilars
  • Human Insulin Biosimilars
  • Device
    • Insulin Pumps
  • Insulin Pump Devices
  • Insulin Pump Reservoirs
  • Insulin Infusion sets
    • Insulin Pens
  • Cartridges in reusable pens
  • Disposable insulin pens
    • Insulin Syringes
    • Insulin Jet Injectors

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan insulin drugs delivery devices market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan insulin drugs delivery devices market?
  • What is the breakup of the Japan insulin drugs delivery devices market on the basis of type?
  • What are the various stages in the value chain of the Japan insulin drugs delivery devices market?
  • What are the key driving factors and challenges in the Japan insulin drugs delivery devices?
  • What is the structure of the Japan insulin drugs delivery devices market and who are the key players?
  • What is the degree of competition in the Japan insulin drugs delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Insulin Drugs Delivery Devices Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Insulin Drugs Delivery Devices Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Insulin Drugs Delivery Devices Market - Breakup by Type

  • 6.1 Drug
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Basal or Long-Acting Insulins
        • 6.1.3.1.1 Lantus (Insulin Glargine)
        • 6.1.3.1.2 Levemir (Insulin Detemir)
        • 6.1.3.1.3 Toujeo (Insulin Glargine)
        • 6.1.3.1.4 Tresiba (Insulin Degludec)
        • 6.1.3.1.5 Basaglar (Insulin Glargine)
      • 6.1.3.2 Bolus or Fast-Acting Insulins
        • 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
        • 6.1.3.2.2 Humalog (Insulin lispro)
        • 6.1.3.2.3 Apidra (Insulin Glulisine)
        • 6.1.3.2.4 FIASP (Insulin Aspart)
        • 6.1.3.2.5 Admelog (Insulin lispro Sanofi)
      • 6.1.3.3 Traditional Human Insulins
        • 6.1.3.3.1 Novolin/Mixtard/Actrapid/Insulatard
        • 6.1.3.3.2 Humulin
        • 6.1.3.3.3 Insuman
      • 6.1.3.4 Combination Insulins
        • 6.1.3.4.1 NovoMix (Biphasic Insulin aspart)
        • 6.1.3.4.2 Ryzodeg (Insulin Degludec and Insulin aspart)
        • 6.1.3.4.3 Xultophy (Insulin Degludec and Liraglutide)
        • 6.1.3.4.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
      • 6.1.3.5 Biosimilar Insulins
        • 6.1.3.5.1 Insulin Glargine Biosimilars
        • 6.1.3.5.2 Human Insulin Biosimilars
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Device
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 Insulin Pumps
        • 6.2.3.1.1 Insulin Pump Devices
        • 6.2.3.1.2 Insulin Pump Reservoirs
        • 6.2.3.1.3 Insulin Infusion Sets
      • 6.2.3.2 Insulin Pens
        • 6.2.3.2.1 Cartridges in Reusable Pens
        • 6.2.3.2.2 Disposable Insulin Pens
      • 6.2.3.3 Insulin Syringes
      • 6.2.3.4 Insulin Jet Injectors
    • 6.2.4 Market Forecast (2025-2033)

7 Japan Insulin Drugs Delivery Devices Market - Competitive Landscape

  • 7.1 Overview
  • 7.2 Market Structure
  • 7.3 Market Player Positioning
  • 7.4 Top Winning Strategies
  • 7.5 Competitive Dashboard
  • 7.6 Company Evaluation Quadrant

8 Profiles of Key Players

  • 8.1 Company A
    • 8.1.1 Business Overview
    • 8.1.2 Product Portfolio
    • 8.1.3 Business Strategies
    • 8.1.4 SWOT Analysis
    • 8.1.5 Major News and Events
  • 8.2 Company B
    • 8.2.1 Business Overview
    • 8.2.2 Product Portfolio
    • 8.2.3 Business Strategies
    • 8.2.4 SWOT Analysis
    • 8.2.5 Major News and Events
  • 8.3 Company C
    • 8.3.1 Business Overview
    • 8.3.2 Product Portfolio
    • 8.3.3 Business Strategies
    • 8.3.4 SWOT Analysis
    • 8.3.5 Major News and Events
  • 8.4 Company D
    • 8.4.1 Business Overview
    • 8.4.2 Product Portfolio
    • 8.4.3 Business Strategies
    • 8.4.4 SWOT Analysis
    • 8.4.5 Major News and Events
  • 8.5 Company E
    • 8.5.1 Business Overview
    • 8.5.2 Product Portfolio
    • 8.5.3 Business Strategies
    • 8.5.4 SWOT Analysis
    • 8.5.5 Major News and Events

9 Japan Insulin Drugs Delivery Devices Market - Industry Analysis

  • 9.1 Drivers, Restraints and Opportunities
    • 9.1.1 Overview
    • 9.1.2 Drivers
    • 9.1.3 Restraints
    • 9.1.4 Opportunities
  • 9.2 Porters Five Forces Analysis
    • 9.2.1 Overview
    • 9.2.2 Bargaining Power of Buyers
    • 9.2.3 Bargaining Power of Suppliers
    • 9.2.4 Degree of Competition
    • 9.2.5 Threat of New Entrants
    • 9.2.6 Threat of Substitutes
  • 9.3 Value Chain Analysis

10 Appendix